We Think NeuroSense Therapeutics (NASDAQ:NRSN) Can Afford To Drive Business Growth

ByFreda D. Cuevas

Mar 28, 2022 #2021 Acura Rdx Technology Package, #2021 Acura Tlx Technology Package, #2022 Acura Mdx Technology Package, #Align Technology Stock, #Applied Racing Technology, #Artificial Intelligence Technology Solutions Inc, #Assisted Reproductive Technology, #Battery Technology Stocks, #Benjamin Franklin Institute Of Technology, #Chief Technology Officer, #Color Star Technology, #Craft Design Technology, #Definition Of Technology, #Definitive Technology Speakers, #Element Materials Technology, #Health Information Technology Salary, #Ice Mortgage Technology, #Information Technology Definition, #Information Technology Degree, #Information Technology Salary, #Interactive Response Technology, #International Game Technology, #La Crosse Technology Weather Station, #Lacrosse Technology Atomic Clock, #Luokung Technology Stock, #Marvell Technology Stock Price, #Maytag Commercial Technology Washer, #Microchip Technology Stock, #Micron Technology Stock Price, #Mrna Technology History, #Mrna Vaccine Technology, #Nyc College Of Technology, #Penn College Of Technology, #Recombinant Dna Technology, #Rlx Technology Stock, #Robert Half Technology, #Science And Technology, #Sharif University Of Technology, #Smart Home Technology, #Stevens Institute Of Technology Ranking, #Symphony Technology Group, #Technology In The Classroom, #Technology Readiness Level, #Technology Stores Near Me, #Thaddeus Stevens College Of Technology, #University Of Advancing Technology, #Vanguard Information Technology Etf, #Vanguard Technology Etf, #What Is 5g Technology, #Women In Technology

[ad_1]

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you’d have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So, the natural question for NeuroSense Therapeutics (NASDAQ:NRSN) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we’ll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We’ll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for NeuroSense Therapeutics

How Long Is NeuroSense Therapeutics’ Cash Runway?

A company’s cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In June 2021, NeuroSense Therapeutics had US$994k in cash, and was debt-free. Importantly, its cash burn was US$750k over the trailing twelve months. Therefore, from June 2021 it had roughly 16 months of cash runway. While that cash runway isn’t too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis

debt-equity-history-analysis

How Is NeuroSense Therapeutics’ Cash Burn Changing Over Time?

NeuroSense Therapeutics didn’t record any revenue over the last year, indicating that it’s an early stage company still developing its business. So while we can’t look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With the cash burn rate up 16% in the last year, it seems that the company is ratcheting up investment in the business over time. However, the company’s true cash runway will therefore be shorter than suggested above, if spending continues to increase. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For NeuroSense Therapeutics To Raise More Cash For Growth?

Given its cash burn trajectory, NeuroSense Therapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. By comparing a company’s annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

NeuroSense Therapeutics’ cash burn of US$750k is about 1.1% of its US$68m market capitalisation. That means it could easily issue a few shares to fund more growth, and might well be in a position to borrow cheaply.

How Risky Is NeuroSense Therapeutics’ Cash Burn Situation?

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought NeuroSense Therapeutics’ cash burn relative to its market cap was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we’re not too worried about its rate of cash burn. On another note, we conducted an in-depth investigation of the company, and identified 6 warning signs for NeuroSense Therapeutics (3 make us uncomfortable!) that you should be aware of before investing here.

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

[ad_2]

Source link